Cargando…

Millepachine, a potential topoisomerase II inhibitor induces apoptosis via activation of NF-κB pathway in ovarian cancer

Millepachine (MIL) was a novel chalcone that was separated from Millettia pachycarpa Benth (Leguminosae). We found MIL induced apoptosis through activating NF-κB pathway both in SK-OV-3 and A2780S cells. Western blot showed that MIL increased the levels of IKKα, p-IKKα/β, p-IκBα and NF-κB (p65) prot...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wu, Wenshuang, Ma, Buyun, Ye, Haoyu, Wang, Taijin, Wang, Xiaoyan, Yang, Jianhong, Wei, Yuquan, Zhu, Jingqiang, Chen, Lijuan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2016
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5239551/ https://www.ncbi.nlm.nih.gov/pubmed/27447570 http://dx.doi.org/10.18632/oncotarget.10739

Ejemplares similares

Differential regulation of NF-κB activation and function by topoisomerase II inhibitors
por: Campbell, Kirsteen J, et al.
Publicado: (2006)

Novel Indole-Containing Hybrids Derived from Millepachine: Synthesis, Biological Evaluation and Antitumor Mechanism Study
por: Liang, Baoxia, et al.
Publicado: (2023)

CD26/dipeptidyl peptidase IV enhances expression of topoisomerase II alpha and sensitivity to apoptosis induced by topoisomerase II inhibitors
por: Sato, K, et al.
Publicado: (2003)

Pharmacological targeting of NF-κB potentiates the effect of the topoisomerase inhibitor CPT-11 on colon cancer cells
por: Lagadec, P, et al.
Publicado: (2008)

Hyperthermia, thermotolerance and topoisomerase II inhibitors.
por: Kampinga, H. H.
Publicado: (1995)

p53-dependent apoptosis is essential for the antitumor effect of paclitaxel response to DNA damage in papillary thyroid carcinoma
por: Wu, Wenshuang, et al.
Publicado: (2021)

Isogambogenic acid induces apoptosis-independent autophagic cell death in human non-small-cell lung carcinoma cells
por: Yang, Jianhong, et al.
Publicado: (2015)

Author Correction: Isogambogenic acid induces apoptosis-independent autophagic cell death in human non-small-cell lung carcinoma cells
por: Yang, Jianhong, et al.
Publicado: (2020)

Prognostic role of topoisomerase-IIα in advanced ovarian cancer patients
por: Ferrandina, G, et al.
Publicado: (2008)

DNA topoisomerase IIα and -β expression in human ovarian cancer
por: Withoff, S, et al.
Publicado: (1999)

Mechanisms regulating resistance to inhibitors of topoisomerase II
por: Ganapathi, Ram N., et al.
Publicado: (2013)

Activity of M3814, an Oral DNA-PK Inhibitor, In Combination with Topoisomerase II Inhibitors in Ovarian Cancer Models
por: Wise, Hannah C., et al.
Publicado: (2019)

Relationship between expression of topoisomerase II isoforms and intrinsic sensitivity to topoisomerase II inhibitors in breast cancer cell lines.
por: Houlbrook, S., et al.
Publicado: (1995)

Relationship between expression of topoisomerase II isoforms and intrinsic sensitivity to topoisomerase II inhibitors in breast cancer cell lines
Publicado: (1996)

NF-κB Signaling in Ovarian Cancer
por: Harrington, Brittney S., et al.
Publicado: (2019)

A Topoisomerase II Inhibitor, NK109, Induces DNA Single‐ and Double‐strand Breaks and Apoptosis
por: Fukuda, Minoru, et al.
Publicado: (1996)

Polymorphisms in NF-κB Inhibitors and Risk of Epithelial Ovarian Cancer
por: White, Kristin L, et al.
Publicado: (2009)

Chromatinization Modulates Topoisomerase II Processivity
por: Lee, Jaeyoon, et al.
Publicado: (2023)

Chromatinization modulates topoisomerase II processivity
por: Lee, Jaeyoon, et al.
Publicado: (2023)

UFL1 Alleviates LPS-Induced Apoptosis by Regulating the NF-κB Signaling Pathway in Bovine Ovarian Granulosa Cells
por: Wang, Xinling, et al.
Publicado: (2020)

Immunosuppression through constitutively activated NF-κB signalling in human ovarian cancer and its reversal by an NF-κB inhibitor
por: Nishio, H, et al.
Publicado: (2014)

Synthesis, activity, and docking study of phenylthiazole acids as potential agonists of PPARγ
por: Ma, Liang, et al.
Publicado: (2016)

Roles of the C-terminal domains of topoisomerase IIα and topoisomerase IIβ in regulation of the decatenation checkpoint
por: Kozuki, Toshiyuki, et al.
Publicado: (2017)

DUSP1 mediates BCG induced apoptosis and inflammatory response in THP-1 cells via MAPKs/NF-κB signaling pathway
por: Liu, Zhanyou, et al.
Publicado: (2023)

BRD4 inhibition promotes TRAIL-induced apoptosis by suppressing the transcriptional activity of NF-κB in NSCLC
por: Shi, Liu, et al.
Publicado: (2021)

Ciprofloxacin is a potential topoisomerase II inhibitor for the treatment of NSCLC
por: KLOSKOWSKI, TOMASZ, et al.
Publicado: (2012)

Discovery of New Catalytic Topoisomerase II Inhibitors for Anticancer Therapeutics
por: Matias-Barrios, Victor M., et al.
Publicado: (2021)

The Implication of Topoisomerase II Inhibitors in Synthetic Lethality for Cancer Therapy
por: Matias-Barrios, Victor M., et al.
Publicado: (2023)

Localization of topoisomerase II in mitotic chromosomes
Publicado: (1985)

Topoisomerase II has to work late
por: Leslie, Mitch
Publicado: (2014)

Diversity and Functions of Type II Topoisomerases
por: Sutormin, D. A., et al.
Publicado: (2021)

Galectin-1 promotes tumor progression via NF-κB signaling pathway in epithelial ovarian cancer
por: Chen, Le, et al.
Publicado: (2017)

Natural Products as Topoisomerase II Poisons: Effects of Thymoquinone on DNA Cleavage Mediated by Human Topoisomerase IIα
por: Ashley, Rachel E., et al.
Publicado: (2014)

Inhibition of Topoisomerase IIα and Induction of Apoptosis in Gastric Cancer Cells by 19-Triisopropyl Andrographolide
por: Monger, Adeep, et al.
Publicado: (2017)

Maternal topoisomerase II alpha, not topoisomerase II beta, enables embryonic development of zebrafish top2a(-/- )mutants
por: Sapetto-Rebow, Beata, et al.
Publicado: (2011)

NF-κB inhibitor with Temozolomide results in significant apoptosis in glioblastoma via the NF-κB(p65) and actin cytoskeleton regulatory pathways
por: Avci, Naze G., et al.
Publicado: (2020)

Targeting of topoisomerases for prognosis and drug resistance in ovarian cancer
por: Bai, Yang, et al.
Publicado: (2016)

Chemotherapeutic Drugs Inhibiting Topoisomerase 1 Activity Impede Cytokine-Induced and NF-κB p65-Regulated Gene Expression
por: Riedlinger, Tabea, et al.
Publicado: (2019)

Phase I and pharmacokinetic study of the topoisomerase II catalytic inhibitor fostriecin
por: Jong, R S de, et al.
Publicado: (1999)

Metnase Mediates Resistance to Topoisomerase II Inhibitors in Breast Cancer Cells
por: Wray, Justin, et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_tpvoghhvq03kc34jtd8s348t7j